Latest Healthcare It News

Micro-X has raised $6.18 million through a placement that sees strategic partner Billion Prima increase its stake to 8.6%, funding key commercial and manufacturing scale-up initiatives in medical imaging.

Cleo Diagnostics has raised $5 million to support the U.S. commercial launch of its Pre-Surgical Ovarian Cancer Test and accelerate development of a mass screening test, signaling strong investor confidence in its technology.

Orthocell has reached a significant milestone with 100 units of its nerve repair product Remplir™ sold in the US, signaling accelerating adoption in a $1.6 billion market. The company’s strategic medical education and distributor network are driving momentum ahead of further hospital approvals.

Receivers and administrators have been appointed to 54 pharmacies within the Infinity Retail Pharmacy Group, catching Paragon Care off guard despite ongoing debt restructuring talks. The company pledges to support an orderly resolution to maximise creditor returns.

Memphasys Limited’s partner International Technical Legacy has placed an early order for 500 Felix™ cartridges ahead of anticipated CE Mark approval, signalling strong clinic demand and validating the company’s direct-selling strategy in the Middle East.

Aumake Limited has obtained a Hong Kong pharmaceutical wholesale licence, enabling it to launch up to five online over-the-counter medicine stores targeting Chinese consumers. This strategic move positions the company to tap into China’s rapidly expanding OTC market.

BlinkLab Limited has appointed its Co-Founder and CEO, Dr Henk-Jan Boele, as Managing Director to steer the company through its pivotal FDA 510(k) trial for its autism diagnostic technology. The move coincides with key board changes and signals a strategic shift as BlinkLab prepares for early commercialisation.

HealthCo Healthcare & Wellness REIT confirms full rent payment from Healthscope and has conditional agreements with alternative tenants for its hospital portfolio, while suspending its December quarter distribution to preserve liquidity.

Actinogen Medical has finalized enrollment and begun treatment of all 246 participants in its XanaMIA Phase 2b/3 Alzheimer’s trial, with topline results expected in November 2026. The oral drug Xanamem targets brain cortisol to potentially slow disease progression.

TrivarX Limited has reported compelling clinical trial results demonstrating its single-lead ECG algorithm’s high sensitivity in detecting major depressive episodes among US veterans, marking a significant step in objective mental health screening.

Telix Pharmaceuticals confirms completion of Part 1 enrolment in its ProstACT Phase 3 trial for prostate cancer, with safety data supporting progression to Part 2 and regulatory approvals secured across multiple countries.

Anatara Lifesciences reports encouraging pre-clinical results for its anti-obesity candidate AOC, demonstrating significant reductions in weight regain and visceral fat in mice. However, a delay in mechanism of action studies pushes full data release to January 2026.